![]() ![]() My group focuses on large-scale analyses of germline genetic data from patients treated with immunotherapies, and on integrated analyses of germline and tumor genomic features to identify novel drug targets and biomarkers for precision medicine approaches. It is increasingly likely that the entirety of germline genetic variation impacting how our immune system responds to cancer accounts for some of the observed variability in responses to immune checkpoint blockade. The advent and success of cancer immunotherapies, however, have opened new perspectives for the investigation of the role of inherited genetic variation in co-determining outcome and safety. ![]() The majority of genetics research in oncology has concentrated on the role of tumor somatic mutations, as well as inherited risk variants, in disease susceptibility and response to targeted treatments. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |